≡ Risteys
R10

Documentation Changelog GitHub Contact & Feedback

Haemangioma, any site

DOID EFO MESH SNOMED Endpoint Browser PheWeb

CD2_BENIGN_HEMANGIOMA

hemangioma: A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.

Endpoint definition

↥
FinnGen phenotype data

429209 individuals

diagram downward connector

Apply sex-specific rule None

429209

diagram downward connector

Check conditions None

429209

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D18.0&
Hospital discharge: ICD-9 2280
Hospital discharge: ICD-8 22700
Cause of death: ICD-10 D18.0&
Cause of death: ICD-9 2280
Cause of death: ICD-8 22700

2 out of 7 registries used, show all original rules.

2609

diagram downward connector

Check minimum number of events None

2609

diagram downward connector

Include endpoints None

2609

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

2506

diagram downward connector
CD2_BENIGN_HEMANGIOMA

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF2
Parent code in ICD-10 D18
Name in latin Haemangioma (quovis loco)

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 2506 1601 905
Unadjusted prevalence (%) 0.61 0.70 0.50
Mean age at first event (years) 47.85 45.61 51.79

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.05 2.14 [1.51, 3.03] 2.1e-5 188
15 years 0.01 1.39 [0.96, 2.02] 7.8e-2 84
5 years 0.00 2.46 [1.61, 3.75] 2.9e-5 50
1 year 0.00 5.36 [3.21, 8.92] 1.2e-10 21

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: CD2_BENIGN_HEMANGIOMA – Haemangioma, any site
GWS hits:

Survival analyses between endpoints

↥

Plot

before Haemangioma, any site
after Haemangioma, any site

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Haemangioma, any site

↥

Endpoint not on priority list, no data to show.